Mnogochislennye issledovaniya svidetel"stvuyut o vzaimnom vliyanii VICh i virusa gepatita S na techenie, kak VICh-infektsii, tak i khronicheskogo gepatita S. Odnoy iz osobennostey infektsii, vyzvannoy HSV, yavlyaetsya vysokiy risk razvitiya khronicheskoy formy bolezni, a pri sochetannoy infektsii HIV/HSV otmechaetsya bolee bystroe progressirovanie khronicheskoy bolezni pecheni i bol"shaya chastota razvitiya tsirroza, chem pri monoinfektsii HCV. S vvedeniem v klinicheskuyu praktiku antiretrovirusnoy terapii VICh-infektsii, uluchshilis" kachestvo i prodolzhitel"nost" zhizni patsientov. Vmeste s tem, posle vnedreniya VAART smertnost" ot bolezney pecheni uvelichilas" s 5-12% do 35-50%. Osnovnye printsipy lecheniya KhGS u VICh-infitsirovannykh sootvetstvuyut takovym u patsientov, ne zarazhennykh VICh. V nastoyashchee vremya, standartom terapii KhGS u VICh-infitsirovannykh patsientov yavlyaetsya naznachenie pegilirovannogo interferona-al"fa i ribavirina v techenie 48 nedel" vne zavisimosti ot genotipa virusa S. Dannykh ob effektivnosti i bezopasnosti kombinirovannoy terapii KhGS u VICh-infitsirovannykh patsientov bez priznakov tsirroza pecheni i ne poluchayushchikh VAART nedostatochno. Issledovaniyu etoy problemy i posvyashchena dannaya rabota.